BI-1808

Kundenbewertung

Based on 1 Customer Validation

BI-1808 is a fully human IgG1 monoclonal antibody targeting human tumor necrosis factor receptor 2 (TNFR2) (KD = 646 pM). BI-1808 inhibits Treg survival by blocking the interaction between TNFR2 and its ligand TNF-α, and via its IgG1 Fc segment binds FcγR to target and deplete intratumoral Tregs (ADCC/ADCP) and induce pro-inflammatory reprogramming of myeloid cells, ultimately activating CD8+ effector T cell-mediated tumor rejection. BI-1808 can produce synergistic antitumor effects with Pembrolizumab (HY-P9902). BI-1808 can be used for research in tumor immunity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • Reinheit : 97.75%
  • Molecular Weight:144.206 kDa
  • Speicherung:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Biologische Aktivität
  • Chemical Information
  • Protokoll
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs
MOQ
Minimum order quantity
100 mg

Angebot einholen Auf Lager

Other size
Angebot einholen
Please select quantity
Amount: USD 0.00